Public Support for COVID-19 Test Allocation
7 gennaio 2022 aggiornato da: Alison Buttenheim, University of Pennsylvania
Race, Status, Vaccines, Tests, and Place: Public Attitudes and Support for Equitable COVID-19 Vaccine and Test Allocation
In a randomized survey experiment, investigators will assess public support or opposition towards one of three potential government plans for allocating at-home coronavirus disease 2019 (COVID-19) tests to United States residents: 1) first come, first served; 2) a random draw; or 3) a random draw with 20% of tests reserved for disadvantaged areas.
Investigators will also examine public attitudes surrounding other logistical and equity-related aspects of these allocation plans.
Panoramica dello studio
Stato
Completato
Condizioni
Descrizione dettagliata
Complementing other efforts to increase access to COVID-19 testing in the United States, the federal government recently announced the purchase of 500,000,000 at home COVID-19 to be distributed for free "to Americans that want them".
A central logistical element in matching supply with demand will be a website, on which people will register their interest in getting tests delivered to their home address.
However, it is still unclear how supply will be matched with demand.
Three main candidate options are first come, first served (FCFS), in which people are sent tests in the order in which they make requests; a random draw, such as a lottery; or a combination of a random draw with a guaranteed reserved amount for more disadvantaged populations.
FCFS is a widely known and practiced rationing principle, but it has shown to exacerbate inequities in, for example, the allocation of vaccine appointments.
Random draws can mitigate this impact, but, in the present context, might be insufficiently sensitive to the fact that not everyone has internet access, and that the need for testing is greater among more disadvantaged communities.
Combining a lottery with a disadvantage reserve system using measures such as the CDC's Social Vulnerability Index is a practical way of promoting equity, and it was already used by the majority of US states in allocating vaccines.
The main objective of this study is to assess public support for each of these three allocation plans and describe differences by demographic characteristics.
Investigators will also assess public attitudes toward specific details of these allocation plans.
The study, which is expected to take approximately 5 minutes to complete, will be administered as part of an omnibus online survey.
Tipo di studio
Interventistico
Iscrizione (Effettivo)
2019
Fase
- Non applicabile
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
District of Columbia
-
Washington, District of Columbia, Stati Uniti, 20006
- Harris Insights & Analytics
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
18 anni e precedenti (Adulto, Adulto più anziano)
Accetta volontari sani
Sì
Sessi ammissibili allo studio
Tutto
Descrizione
Inclusion Criteria:
- Aged 18 years old or older, United States resident
Exclusion Criteria:
- None
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Ricerca sui servizi sanitari
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: First Come, First Served
Respondents will view the following description: "The US government will make 500 million COVID-19 home tests available for free. US residents can ask for tests by entering their home address in a website. It is likely that more people will want tests than will be available. How should the government decide who will receive tests, when there are not enough for all who want them? One plan that is being considered is this one:" Below this statement, respondents will view the "First Come, First Served" plan description. |
Respondents will view the following description of the plan: "Tests will be sent out in the order they are requested.
People who request tests the quickest will get them first, no matter where they live.
People who request tests later may not get any.
This strategy is also known as 'First Come, First Served.'"
|
|
Sperimentale: Random
Respondents will view the following description: "The US government will make 500 million COVID-19 home tests available for free. US residents can ask for tests by entering their home address in a website. It is likely that more people will want tests than will be available. How should the government decide who will receive tests, when there are not enough for all who want them? One plan that is being considered is this one:" Below this statement, respondents will view the "Random" plan description. |
Respondents will view the following description of the plan: "People who request tests will be entered into a random drawing, like a sweepstakes or lottery.
Everyone who is in the drawing has the same chance of getting tests, no matter where they live, but some people may not get any tests."
|
|
Sperimentale: Disadvantaged Priority & Random
Respondents will view the following description: "The US government will make 500 million COVID-19 home tests available for free. US residents can ask for tests by entering their home address in a website. It is likely that more people will want tests than will be available. How should the government decide who will receive tests, when there are not enough for all who want them? One plan that is being considered is this one:" Below this statement, respondents will view the "Disadvantaged Priority & Random" plan description. |
Respondents will view the following description of the plan: "Because COVID-19 has hit people living in disadvantaged areas of the country harder, a proportion of tests will be sent exclusively to people in these zip codes.
Planners will allocate 80% of the tests using a random drawing, like a sweepstakes or lottery.
Everyone who is in the drawing has the same chance of getting tests, no matter where they live.
The remaining 20% are set aside exclusively for the most disadvantaged areas, again allocated with a random drawing.
Some people may not get any tests.
But people living in disadvantaged areas are more likely to get them."
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Support for allocation plan
Lasso di tempo: 5 minutes
|
Self-reported degree of support for the plan, measured on a 5-point Likert scale ("strongly oppose" to "strongly support") that will be collapsed into 3 response categories ("oppose," "neutral," and "support") for analysis.
|
5 minutes
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Household-level test allocation preference
Lasso di tempo: 5 minutes
|
Preferred way of sending tests to households, measured as a binary choice between a fixed or variable (based on household size) number of tests per household.
|
5 minutes
|
|
Tests allocated to disadvantaged areas
Lasso di tempo: 5 minutes
|
Self-reported percentage of tests wanted to be sent to disadvantaged areas, measured as a continuous variable on a slider from 0% to 100% with increments of 0.1%.
This outcome will only be measured for respondents in the "Disadvantaged Priority & Random" condition.
|
5 minutes
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Investigatori
- Investigatore principale: Alison M Buttenheim, PhD, MBA, University of Pennsylvania
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Effettivo)
4 gennaio 2022
Completamento primario (Effettivo)
6 gennaio 2022
Completamento dello studio (Effettivo)
6 gennaio 2022
Date di iscrizione allo studio
Primo inviato
7 gennaio 2022
Primo inviato che soddisfa i criteri di controllo qualità
7 gennaio 2022
Primo Inserito (Effettivo)
11 gennaio 2022
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
11 gennaio 2022
Ultimo aggiornamento inviato che soddisfa i criteri QC
7 gennaio 2022
Ultimo verificato
1 gennaio 2022
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 848725
- #84525 (Identificatore di registro: AsPredicted)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
INDECISO
Descrizione del piano IPD
Only de-identified individual participant data will be shared by Harris Insights & Analytics to the research team.
Each participant will have a unique identifier to protect their confidentiality.
Only authorized research personnel will have access to the data which will be maintained on encrypted hard-drives.
Individual participant data may be made available to other researchers in an open-access repository.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
No
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
No
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .